Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
PLoS One
.
2021 Dec 23;16(12):e0261994.
doi: 10.1371/journal.pone.0261994.
eCollection 2021.
Authors
Manish A Shah
,
Zev A Wainberg
,
Daniel V T Catenacci
,
Howard S Hochster
,
James Ford
,
Pamela Kunz
,
Fa-Chyi Lee
,
Howard Kallender
,
Fabiola Cecchi
,
Daniel C Rabe
,
Harold Keer
,
Anne-Marie Martin
,
Yuan Liu
,
Robert Gagnon
,
Peter Bonate
,
Li Liu
,
Tona Gilmer
,
Donald P Bottaro
PMID:
34941969
PMCID:
PMC8699912
DOI:
10.1371/journal.pone.0261994
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0054014.].
Publication types
Published Erratum